Hexarelin – 5mg (3ml Pen)
The most potent of the classical secretagogues, with a distinctive second research line in cardiac tissue independent of growth hormone. Research use only.
Ghrelin Receptor
Cardiac Research
Growth Hormone Axis
Description
Hexarelin 5mg (3ml Pen) – Growth Hormone Secretagogue Research Peptide
Hexarelin is a synthetic growth hormone-releasing hexapeptide investigated for its effects on pituitary hormone secretion, ghrelin receptor activity and cardiovascular signalling. As a member of the growth hormone secretagogue family, Hexarelin has attracted scientific interest because of its endocrine activity and distinct research findings involving cardiac tissue.
Unlike growth hormone-releasing hormone (GHRH) analogues, Hexarelin primarily stimulates growth hormone secretion through the growth hormone secretagogue receptor GHS-R1a.
Research has also explored interactions involving CD36, a membrane-associated receptor implicated in some of Hexarelin’s cardiovascular effects.
Supplied in a 5mg, 3ml pen format, Hexarelin is relevant to laboratory investigations examining hormonal regulation, receptor desensitisation, cardiac biology and growth hormone-related physiological pathways.
Hexarelin and Growth Hormone Research
Growth hormone contributes to multiple biological processes, including protein metabolism, tissue development and metabolic regulation.
Hexarelin is investigated for its ability to stimulate growth hormone secretion through receptor-mediated signalling at the pituitary and hypothalamic levels.
Research involving Hexarelin has focused on several important mechanisms:
- Growth hormone secretion: Investigating pituitary responses following growth hormone secretagogue receptor activation.
- Receptor pharmacology: Studying interactions with GHS-R1a and other molecular targets.
- Muscle physiology: Examining hormonal pathways associated with protein metabolism and tissue regulation.
- Cardiovascular research: Exploring receptor-mediated responses in cardiac and vascular tissues.
- Endocrine regulation: Investigating cortisol, prolactin and other hormonal responses.
- Receptor desensitisation: Understanding changes in signalling following repeated receptor activation.
Although growth hormone signalling is involved in muscle physiology, there is insufficient clinical evidence that Hexarelin improves muscle mass, strength, recovery or athletic performance.
Researchers investigating related compounds can explore our selection of growth and performance peptides for laboratory research, including compounds studied for their effects on growth hormone signalling and muscle-related biological processes.
How Does Hexarelin Work?
Hexarelin interacts with several molecular pathways, making its research profile broader than that of some other growth hormone secretagogues.
GHS-R1a Receptor Activation
Hexarelin acts as an agonist at the growth hormone secretagogue receptor GHS-R1a, which is also activated by the naturally occurring hormone ghrelin.
Receptor activation stimulates intracellular signalling involving phospholipase C and calcium mobilisation, contributing to growth hormone secretion.
This pathway differs from the cyclic AMP signalling associated with GHRH receptor stimulation.
Pituitary Growth Hormone Release
Experimental investigations have demonstrated that Hexarelin stimulates growth hormone secretion from pituitary somatotroph cells.
The magnitude of the response can vary according to physiological conditions, previous receptor exposure and other endocrine influences.
CD36 and Cardiovascular Signalling
An important distinguishing feature of Hexarelin research is its interaction with CD36, a scavenger receptor expressed in several tissues, including cardiovascular structures.
Preclinical studies have explored whether CD36-mediated activity contributes to the cardiovascular responses observed with Hexarelin.
This research is separate from the compound’s conventional growth hormone secretagogue activity and remains an area of experimental investigation.
Receptor Desensitisation
Repeated activation of growth hormone secretagogue receptors can lead to reduced cellular responsiveness.
Laboratory research involving Hexarelin has demonstrated rapid desensitisation of GHS-R1a-associated calcium signalling.
This finding has implications for understanding receptor regulation and interpreting experimental responses over time.
Hexarelin and Muscle Physiology Research
Growth hormone influences protein metabolism, tissue regulation and physiological processes associated with skeletal muscle.
Hexarelin provides researchers with a compound for investigating how growth hormone secretagogue signalling contributes to these biological pathways.
Relevant research areas include:
Protein Metabolism
Investigating relationships between endocrine signalling, protein turnover and the maintenance of skeletal muscle tissue.
Growth Hormone Regulation
Examining the mechanisms that control growth hormone secretion and the interactions between stimulatory and inhibitory endocrine pathways.
Tissue Development
Studying the relationship between growth hormone activity and downstream signalling systems involved in tissue growth.
Metabolic Function
Exploring growth hormone-related pathways associated with energy metabolism and nutrient regulation.
While these mechanisms provide a scientific rationale for investigating Hexarelin in muscle physiology research, direct evidence of performance-enhancing or muscle-building effects in humans remains insufficient.
Cardiovascular Research and Hexarelin
One of the most distinctive areas of Hexarelin research involves its effects on cardiac tissue.
Cardiac Receptor Activity
Studies have identified interactions between Hexarelin and receptor systems expressed in cardiac tissue, including CD36.
These findings suggest that certain cardiovascular responses may occur through mechanisms separate from pituitary growth hormone secretion.
Experimental Cardiac Function
Small human studies have reported short-term changes in left ventricular function following Hexarelin exposure.
However, these findings do not establish long-term cardiovascular benefits or demonstrate that Hexarelin is an effective treatment for heart disease.
Cardiomyocyte Research
Preclinical investigations have explored potential effects on cardiomyocyte survival and cellular responses to experimental injury.
These findings remain preliminary and require further investigation before clinical conclusions can be drawn.
Growth Hormone-Independent Mechanisms
Some experimental findings suggest that Hexarelin may influence cardiac function independently of measurable changes in circulating growth hormone.
This distinction is important because it separates the compound’s endocrine activity from its additional cardiovascular research applications.
Scientific Research Findings
1. Growth Hormone Secretagogue Activity
Hexarelin has been studied for its substantial growth hormone-releasing effects.
Comparative research involving other synthetic secretagogues has examined differences in potency, receptor activation and endocrine responses.
2. Ghrelin Receptor Desensitisation
Laboratory studies have demonstrated that repeated Hexarelin stimulation can reduce subsequent GHS-R1a signalling responses.
This research contributes to understanding receptor regulation and the mechanisms influencing growth hormone secretagogue activity.
3. Cardiovascular Receptor Pharmacology
Investigations involving Hexarelin have explored CD36 receptor interactions and their possible involvement in cardiovascular responses.
This remains one of the compound’s most distinctive research characteristics.
4. Hormonal Selectivity
Hexarelin can influence additional endocrine pathways beyond growth hormone secretion.
Studies have reported cortisol and prolactin responses under certain experimental conditions, making hormonal selectivity an important consideration.
5. Metabolic and Tissue Research
Because growth hormone signalling contributes to metabolic and tissue-related processes, Hexarelin has been investigated as a model compound for studying these endocrine mechanisms.
Research has not established that these effects translate into improved muscle growth or physical performance in humans.
Hexarelin Compared with Other Growth Hormone Secretagogues
Hexarelin belongs to the same broad research class as GHRP-2, GHRP-6 and Ipamorelin, although the compounds differ in their biological activity and research profiles.
Hexarelin: Investigated for strong growth hormone secretagogue activity, receptor desensitisation and cardiovascular signalling.
GHRP-2: Studied for substantial growth hormone secretion and broader pituitary endocrine responses.
GHRP-6: Particularly associated with research involving ghrelin receptors, appetite regulation and growth hormone release.
Ipamorelin: Investigated for a comparatively selective growth hormone secretagogue profile in certain experimental settings.
The additional cardiovascular research involving Hexarelin helps distinguish it from other compounds in this class.
Hexarelin 5mg Product Specifications
- Product: Hexarelin
- Quantity: 5mg
- Format: 3ml pen
- Classification: Synthetic growth hormone-releasing hexapeptide
- Primary receptor: GHS-R1a
- Additional receptor of research interest: CD36
- Primary research focus: Growth hormone secretion and receptor pharmacology
- Additional research areas: Cardiovascular signalling, endocrine regulation and receptor desensitisation
Hexarelin Research from Coridion Sciences
Coridion Sciences supplies specialist research peptides and advanced peptide formulations for laboratory investigation.
Its research catalogue includes compounds investigated across growth hormone regulation, cellular signalling, metabolic processes and tissue physiology.
Hexarelin 5mg is available in a 3ml pen format as part of the company’s wider research peptide range.
Research Use Only: Hexarelin is intended exclusively for scientific and laboratory research. It is not approved for human consumption, medical treatment, cardiovascular therapy or athletic performance enhancement.
Mechanisms of Action
Hexarelin is a synthetic hexapeptide agonist at GHS-R1a with the highest reported secretagogue potency in its structural class. Research additionally documents binding at the CD36 scavenger receptor in cardiac and vascular tissue, mediating effects on cardiomyocyte survival and coronary perfusion that are reported to persist in growth-hormone-deficient models. The literature also consistently describes attenuation of the growth hormone response with repeated exposure, alongside cortisol and prolactin elevation greater than that of selective agonists.
Research Status & Findings
A moderate literature with two distinct strands: endocrine secretagogue pharmacology, and a separate and mechanistically independent body of cardiovascular research.
Cardiac research
Studies on CD36 binding, cardiomyocyte survival and ischaemia models.
Comparative potency
Research reporting the highest GH release magnitude among classical secretagogues.
Desensitisation
Documented attenuation of response with repeated administration in study designs.
Receptor pharmacology
Characterisation of dual GHS-R1a and CD36 binding.
Selectivity profile
Work documenting cortisol and prolactin involvement relative to selective agonists.
*For research purposes only – not for human consumption*
As Seen In The Press
Peptides can affect the way the body functions at a cellular level.

Our 3 Step System
Pre-filled Cartridges
Engineered for absolute accuracy and ease. Our pre-blended pens make precise dosing completely seamless in just three quick steps.
Step 1 - Remove the Pre-mixed pen from the box
Step 2 - Secure the needle tip
Step 3 - Twist to set the required dose
Blends
Blends
Sermorelin + GHRP-6 – 5mg / 5mg (3ml Pen)
Sermorelin + GHRP-6 5mg/5mg combines a 29-amino-acid GHRH analogue with a synthetic ghrelin receptor agonist. Investigated for complementary growth hormone signalling pathways, pituitary hormone. Research use only.
£95.00
Blends
Sermorelin + GHRP-2 – 5mg / 5mg (3ml Pen)
Sermorelin + GHRP-2 5mg/5mg combines a 29-amino-acid GHRH analogue with a synthetic growth hormone secretagogue. Investigated for complementary pituitary signalling, ghrelin receptor activation and. Research use only.
£99.00
Blends
Longevity Blend (Glutathione / NAD+ / Resveratrol) – 500mg / 100mg / 500mg (3ml Pen)
Three pillars of cellular ageing research in one pen. Pairs antioxidant defence, NAD+ coenzyme power, and sirtuin-modulating activity. Research use only. Research use only.
£129.00
Blends
Vitality Blend (Glutathione / NMN / Resveratrol) – 500mg / 500mg / 500mg (3ml Pen)
The NAD+ precursor evolution. Swaps direct NAD+ for NMN — the biosynthetic precursor the cell uses via the salvage pathway. Research use only. Research use only.
£129.00
Blends
SS-31 + MOTS-c – 10mg / 10mg (3ml Pen)
Two mitochondrial compounds acting on different layers of the same biology — membrane structure and mitokine signalling. Research use only. Research use only.
£139.00
Blends
SS-31 + MOTS-c + NAD+ – 10mg / 10mg / 200mg (3ml Pen)
The flagship triple combination of mitochondrial research. SS-31, MOTS-c and NAD+ each act on a different layer of cellular energy biology — structure, signal. Research use only.
£159.00
Blends
KLOW Blend Peptide – BPC-157, TB-500, KPV & GHK-Cu (3ml Pen)
KLOW Blend Peptide combines BPC-157 10mg, TB-500 10mg, KPV 10mg and GHK-Cu 50mg in a four-component research formulation. The blend brings together compounds studied. Research use only.
£105.00
Blends
CJC-1295 (No DAC) + Ipamorelin + GHRP-2 – 3mg / 3mg / 3mg (3ml Pen)
A three-component preparation pairing a GHRH analogue with both a selective and a higher-potency ghrelin agonist. Research use only. Research use only.
£95.00
Blends
Glow Blend Peptide – BPC-157, TB-500 & GHK-Cu (3ml Pen)
Glow Blend Peptide combines GHK-Cu 50mg, BPC-157 10mg and TB-500 10mg in a three-component research formulation. Its ingredients have been investigated individually for extracellular. Research use only.
£95.00
